NovaTests
Financiado
The first predictive test for radio sensitivity. A step towards an improved and...
The first predictive test for radio sensitivity. A step towards an improved and personalised radiation therapy cancer treatment.
Each year, two out of three cancer patients undergo radiation therapy, meaning close to 1.5M patients in Europe and 2M in the US. However, scientific evidences prove a direct link between radiation therapy and several serious late...
Each year, two out of three cancer patients undergo radiation therapy, meaning close to 1.5M patients in Europe and 2M in the US. However, scientific evidences prove a direct link between radiation therapy and several serious late effects. This because patient’s tolerance to radiation vary significantly and radiotherapy affects indiscriminately both healthy and cancer cells, damaging also active working cells, tissues or organs around the tumour. There is, therefore, an unmet clinical need to tailor treatments to each patient’s unique biology. NovaTests are the first predictive radio-sensitivity tests for cancer treatment. By analysing a simple blood sample, in one week time, we can determine with high accuracy (over 90%) not only whether a patient is sensitive or not to radiation but also how sensitive the patient is. We allow for more efficient treatments and improved quality of cancer survivors, not only during radiation treatments but for the rest of their lives. Our first test, the NovaGray Breast® is aimed at measuring radiosensitivity for breast cancer patients. It meets all regulatory requirements of the 98/79 directive pertaining to the in-vitro diagnostic medical devices, has been stamped with the CE marking in February 2016. So far, €0.5M million have been invested into the development and testing of technology to ensure its robustness and efficiency and move into the next stage of tests development and validation. Within the overall project, we intend to scale-up the process by automating it and run a multi-centre clinical trial to validate the reliability of the test. Further ongoing developments include the extension of the technology to prostate and lung cancers. The proposed work in Phase 1 of the SME instrument fits into our overall plan to reach the market by contributing the financial resources needed to plan a fast sound wider deployment of NovaTests and their market uptake.
ver más
Duración del proyecto: 4 meses
Fecha Inicio: 2018-05-12
Fecha Fin: 2018-09-30
Fecha Fin: 2018-09-30
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2018-09-30
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
EIC-SMEInst-2018-2020:
SME instrument
Cerrada
hace 6 años
Presupuesto
El presupuesto total del proyecto asciende a
71K€
Líder del proyecto
NOVAGRAY
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
265.30K€ |
Participante